Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | PRKACA | P17612 | 1/20 | 0.35 |
| ▸ | LTK | P29376 | 1/20 | 0.35 |
| ▸ | GRK5 | P34947 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17768876 | 0.83 | NPSR1 (0.41) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL22551928 | 0.82 | NPSR1 (0.40) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL28353230 | 0.78 | NPSR1 (0.54) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL14891967 | 0.77 | PLAU (0.53) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL30206694 | 0.74 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL6617911 | 0.74 | NPSR1 (0.48) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL10321291 | 0.72 | NPSR1 (0.47) | NPSR1KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL20773385 | 0.71 | HCRTR2 (0.42) | NPSR1HCRTR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29424930 | 0.70 | NPSR1 (0.40) | NPSR1HCRTR2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22288673 | 0.70 | NPSR1 (0.40) | NPSR1HCRTR2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181092-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-05-04 | — | — | US | disclosed |
| US-11571420-B2 | Pyrazine compounds and uses thereof | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2023-02-07 | — | — | US | disclosed |
| CN-115181092-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-112279837-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-111747954-B | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-08-24 | — | — | CN | disclosed |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-08-19 | — | — | US | disclosed |
| CN-112279837-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-10898481-B2 | Pyrazine compounds and uses thereof | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2021-01-26 | — | — | US | disclosed |
| CN-112055709-A | Pyrazine compounds and uses thereof | 迪哲(江苏)医药股份有限公司 | 2020-12-08 | — | — | CN | disclosed |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| CN-111747954-A | Pyrazine compounds and uses thereof | 迪哲（江苏）医药有限公司 | 2020-10-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10898481-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | NPSR1 201/4885HCRTR2 1525/4885KDM4E 4220/4885 |
| US-20230135068-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | NPSR1 201/4885HCRTR2 1525/4885KDM4E 4220/4885 |
| US-11571420-B2 | Pyrazine compounds and uses thereof | ADORA2A, ADORA2B, ADORA1 | NPSR1 201/4885HCRTR2 1525/4885KDM4E 4220/4885 |
| US-20200330458-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | NPSR1 201/4885HCRTR2 1525/4885KDM4E 4220/4885 |
| US-20210251989-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | ADORA2A, ADORA2B, ADORA1 | NPSR1 201/4885HCRTR2 1525/4885KDM4E 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.